Adequan® I.A. (polysulfated glycosaminoglycan) obtained the approval of the Food and Drug Administration (FDA) for intra-articular injection in 1984.
Adequan® I.A. is the only FDA-approved, effective, intra-articular injectable treatment for equine non-infectious degenerative joint disease. Available only by prescription from your veterinarian, Adequan® i.a. has a 19-year safety record and is backed by numerous clinical studies that show it to be effective. It's the ONLY joint therapy clinically proven to relieve the symptoms AND treat the underlying causes of equine non-infectious degenerative joint disease.
Benefits of Adequan® I.A.:
Adequan® I.A. relieves pain.
Adequan® I.A. blocks enzymes that damage joints.
Adequan® I.A. improves joint lubrication.
Adequan® I.A. inhibits further cartilage degeneration.
Usage and Dosing
The recommended dose of Adequan® I.A. in horses is 250 mg once a week for five weeks intra-articularly. The joint area must be shaved, cleansed and sterilized as in a surgical procedure prior to injection. Do not mix Adequan® I.A. with other drugs or solvents.
Inflammatory joint reactions and septic arthritis have been reported following administration of Adequan® I.A. Joint sepsis, a rare but potentially life threatening complication, can occur after intra-articular injection. Use only in the carpal joint of horses. Do not use in horses intended for human consumption.